KRAS and cancer: They found that shortly after treatment, some cancer cells enter a quiescent state with low KRAS activity, while others bypass inhibition by producing newly synthesised KRASG12C, which is maintained in an active, drug‐insensitive state via EGFR‐ and AURKA‐driven signalling.